A Prospective Cohort Study on the Efficacy and Safety Comparison of Tofacitinib Citrate Tablets Combined With Acitretin Capsules Versus Acitretin Capsules Alone in the Treatment of Primary Cutaneous Amyloidosis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The aim of this clinical trial is to find out whether the combination of tocilizumab tablets and acitretin capsules is more effective than acitretin capsules alone in treating primary cutaneous amyloidosis. It will also investigate the safety of the combination of tocilizumab tablets and acitretin capsules. The main questions it aims to answer are: 1. Does the combination of tocilizumab tablets and acitretin capsules relieve the pruritus symptoms of the participants faster and reduce the pruritus score more than acitretin capsules alone? 2. What medical problems will the participants encounter when taking tocilizumab tablets combined with acitretin capsules? The researchers compared the combination of tocilizumab tablets and acitretin capsules with acitretin capsules alone to see if the combination could better treat primary cutaneous amyloidosis without causing serious adverse reactions. Participants will: 1. Take the combination of tocilizumab tablets and acitretin capsules or acitretin capsules alone every day for 16 weeks. 2. Visit the clinic once every 4 weeks for checkups and tests. 3. Observe participants at 4 weeks, 12 weeks and 24 weeks after discontinuation of medication to determine the recurrence status. 4. Collect the visual analogue scale (VAS) scores for pruritus, symptom severity (SCORAD) scores , rash area and severity, treatment response (EASI) scores, dermatological quality of life index (DLQI), and insomnia severity index (ISI) of participants before and after treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age ≥ 18 years old, without infectious diseases such as hepatitis B and tuberculosis and major underlying diseases (gender not limited);

⁃ Outpatient Diagnosis includes primary cutaneous amyloidosis, macular amyloidosis or lichen amyloidosis;

‣ Visited the outpatient department for PCA treatment for 4 times or more;

∙ The medication record shows Avastin Capsules and/or Tofacitinib Citrate;

• The medical record fully records baseline characteristics, medication dosage, efficacy assessment and adverse events.

Locations
Other Locations
China
Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University)
RECRUITING
Chongqing
Contact Information
Primary
Rui Yin, MD
swyinrui@tmmu.edu.cn
15823265888
Backup
Shiyu Lin, MS
linshiyu@tmmu.edu.cn
15922662986
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2025-12
Participants
Target number of participants: 56
Treatments
Experimental: Experimental group
Take oral Acitretin capsules, 10mg each time, twice a day, for a continuous period of 16 weeks; at the same time, take Tofactinib tablets, 5mg each time, twice a day, for a continuous period of 16 weeks.
Active_comparator: Control group
Take oral Acitretin capsules, 10mg each time, twice a day, for a continuous course of 16 weeks.
Sponsors
Leads: Army Medical University, China

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.